Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension

Trifluoperazine (TFP), an antipsychotic drug approved by the Food and Drug Administration, has been show to exhibit anti-cancer effects. Pulmonary arterial hypertension (PAH) is a devastating disease characterized by a progressive obliteration of small pulmonary arteries (PAs) due to exaggerated pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Grobs, Yann, Awada, Charifa, Lemay, Sarah-Eve, Romanet, Charlotte, Bourgeois, Alice, Toro, Victoria, Nadeau, Valérie, Shimauchi, Kana, Orcholski, Mark, Breuils-Bonnet, Sandra, Tremblay, Eve, Provencher, Steeve, Paulin, Roxane, Boucherat, Olivier, Bonnet, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998101/
https://www.ncbi.nlm.nih.gov/pubmed/33805714
http://dx.doi.org/10.3390/ijms22062919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998101/
https://www.ncbi.nlm.nih.gov/pubmed/33805714
http://dx.doi.org/10.3390/ijms22062919

Ejemplares similares